European Society of Cardiology Congress

Poushali Mukherjea, PhD, Executive Director, Global Medical Affairs, Bristol-Myers Squibb, noted some key takeaways from her team's 19 abstracts slated to be presented at the European Society of Cardiology Congress 2016 (ESC).

The European Society of Cardiology's annual conference in London highlighted some of the top work being done in the field over the past year.

PCSK9 inhibitors have been the focus of the cardiology community and with the approval of two medications in the past few months these drugs could soon make their way to a large number of patients needing help managing their cholesterol levels using more than just statins.

Congestive heart failure is a serious condition facing people around the world. Early trials of a gene therapy have showed promise to not only help these patients with the condition but also make their hearts healthier.

Just because researchers go into a study with a hypothesis they hope to prove, it does not mean the results will be what they were hoping for.

Several large groups combined data to look at results of a study on heart failure patients to see whether age and gender affected treatment options prescribed by patients.

Treating one patient for an illness can answer some questions for doctors. However, in many cases looking at the larger patient population can answer not only why the patients got sick, but what can be done to keep them healthy in the long run.

In the time since Florence Nightingale first developed the profession of nursing as it is known today a lot has changed for the men and women in the field. Even still the work they do has been a key part of the medical world as training has increased and improved as well.

The glucose-lowering medication lixisenatide was found not neither increase nor decrease cardiovascular (CV) events compared with placebo in patients afflicted with type 2 diabetes and acute coronary syndrome.

There could be a new first-line treatment for hypertension in patients needing diuretic therapy, according to research presented at the European Society of Cardiology (ESC) Congress conference in London, UK.

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.